Fresenius Kabi USA, LLC: Drug Recall

Recall #D-0129-2023 · 11/22/2022

Class II: Risk

Recall Details

Recall Number: D-0129-2023
Classification: Class II
Product Type: Drug
Recalling Firm: Fresenius Kabi USA, LLC
Status: Terminated
Date Initiated: 11/22/2022
Location: Lake Zurich, IL, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 31,600 vials

Reason for Recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Product Description

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Distribution Pattern

Nationwide in the USA

Other Recalls by Fresenius Kabi USA, LLC

Class II: Risk 11/21/2025

Emphasizing instructions for LVP duration programming located in the IFU.
Class I: Dangerous 11/14/2025

Software version 5.10.1 and earlier contain anomalies that have the potential to cause serious patient harm or death.
Class I: Dangerous 11/06/2025

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Class II: Risk 11/03/2025

Downstream Occlusion alarms may occur during procedures using low flow infusion rates when a check valve* is added to the Ivenix Administration Set.
Class I: Dangerous 11/03/2025

Incorrect assembly of specific lot of LVP Primary Administration Set that could result in serious patient injury.

View all recalls by Fresenius Kabi USA, LLC →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.